Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

OrigiMed and Bayer Partner on Gene Fusion Companion Diagnostic

publication date: May 1, 2020

OrigiMed (Shanghai), a precision medicine company, formed a collaboration with Germany's Bayer to develop a China in vitro companion diagnostic (CDx-IVD) to detect NTRK gene fusions. Bayer's larotrectinib (Vitrakvi®) is a TRK inhibitor approved in the US (2018) and EU (2019) to treat adult and pediatric patients with solid tumor TRK fusion cancers. Larotrectinib is being developed globally, including in China. OrigiMed uses high-throughput analysis together with bioinformatics and clinical data to match patients with targeted therapies, immunotherapies and clinical trials. More details...

Stock Symbol: (XETRA: BAYN)

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.